In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tanox: Once Is Not Enough

Executive Summary

Double-digit royalties from the sales of an expected blockbuster allergy and asthma drug make Tanox a biotech player. But it still hasn't proven itself as a drug developer. Where does Tanox go from here?The company has a significant share of E25, a monoclonal antibody now under worldwide regulatory review as an asthma/allergy treatment. Tanox partnered its anti-IgE progam with Novartis (then Ciba-Geigy) in 1990. After Genentech disclosed its own anti-IgE program in 1993, triggering a lawsuit by Tanox and Novartis, the parties settled and Genentech also became a partner. The tripartite collaboration picked E25--Genentech's compound--for development a year later. Since then, Tanox's collaborators have shouldered the responsibility for commercialization of E25. It effectively lost the chance to build a commercial infrastructure around a major program and demonstrate its ability to manage late-stage product development. However, having large-company partners did enable Tanox to begin building a modest pipeline with early-stage in-licensed and homegrown products, including Hu 901, its own anti-IgE antibody now in human testing for severe peanut allergies. Tanox also significantly enhanced its power to partner when it went public in April, raising $226 million. It now sports a roughly $2 billion valuation. To drive growth and be more than a revenue stream for E25, however, management must now demonstrate a new range of deal-making and development capabilities.

You may also be interested in...

Share the Wealth? No Thanks

Biopharmaceutical companies are doing the math and increasingly coming to one conclusion: it's in their economic interests to buy out a biotech partner. Genentech Inc.'s $919 million all-cash acquisition of its omalizumab (Xolair) partner Tanox Inc. in November is one of the most recent examples.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts